Latest & greatest articles for carvedilol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on carvedilol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on carvedilol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for carvedilol

21. Reimbursement claims analysis of outcomes with carvedilol and metoprolol

Reimbursement claims analysis of outcomes with carvedilol and metoprolol Reimbursement claims analysis of outcomes with carvedilol and metoprolol Reimbursement claims analysis of outcomes with carvedilol and metoprolol Luzier A B, Antell L A, Chang L L, Xuan J W, Roth D A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of carvedilol and metoprolol, two beta-blockers, for the treatment of heart failure (HF). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with HF. The inclusion criteria specified patients aged between 18 and 64 years with the following: two in- or outpatient medical claims with HF (International

NHS Economic Evaluation Database.2002

22. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs

Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs Fowler M B, Vera-Llonch N, Oster G, Bristow M R, Cohn J N, Colucci W S, Gilbert E M, Lukas M A, Lacey M J, Richner R, Young S T, Packer M Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A strategy of adding carvedilol to current treatment regimes for patients with heart failure was evaluated. Current treatment regimes included diuretics, digoxin and angiotensin-converting enzyme (ACE) inhibitors. Patients tolerating

NHS Economic Evaluation Database.2001

23. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. 11333992 2001 04 24 2001 05 10 2013 05 28 0028-4793 344 18 2001 May 03 The New England journal of medicine N. Engl. J. Med. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. 1358-65 The benefits of angiotensin-converting-enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown (...) whether race influences the response to carvedilol in patients with chronic heart failure. In the U.S. Carvedilol Heart Failure Trials Program, 217 black and 877 nonblack patients (in New York Heart Association class II, III, or IV and with a left ventricular ejection fraction of no more than 0.35) were randomly assigned to receive placebo or carvedilol (at doses of 6.25 to 50 mg twice daily) for up to 15 months. The effects of carvedilol on ejection fraction, clinical status, and major clinical

NEJM2001

24. Effect of carvedilol on survival in severe chronic heart failure.

Effect of carvedilol on survival in severe chronic heart failure. 11386263 2001 05 16 2001 06 07 2013 05 28 0028-4793 344 22 2001 May 31 The New England journal of medicine N. Engl. J. Med. Effect of carvedilol on survival in severe chronic heart failure. 1651-8 Beta-blocking agents reduce the risk of hospitalization and death in patients with mild-to-moderate heart failure, but little is known about their effects in severe heart failure. We evaluated 2289 patients who had symptoms of heart (...) failure at rest or on minimal exertion, who were clinically euvolemic, and who had an ejection fraction of less than 25 percent. In a double-blind fashion, we randomly assigned 1133 patients to placebo and 1156 patients to treatment with carvedilol for a mean period of 10.4 months, during which standard therapy for heart failure was continued. Patients who required intensive care, had marked fluid retention, or were receiving intravenous vasodilators or positive inotropic drugs were excluded. There were

NEJM2001

25. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. 11356434 2001 05 17 2001 05 31 2015 06 16 0140-6736 357 9266 2001 May 05 Lancet (London, England) Lancet Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. 1385-90 The beneficial effects of beta-blockers on long-term outcome after acute myocardial infarction were shown (...) before the introduction of thrombolysis and angiotensin-converting-enzyme (ACE) inhibitors. Generally, the patients recruited to these trials were at low risk: few had heart failure, and none had measurements of left-ventricular function taken. We investigated the long-term efficacy of carvedilol on morbidity and mortality in patients with left-ventricular dysfunction after acute myocardial infarction treated according to current evidence-based practice. In a multicentre, randomised, placebo

Lancet2001

26. Cost effectiveness of carvedilol for heart failure

Cost effectiveness of carvedilol for heart failure Cost effectiveness of carvedilol for heart failure Cost effectiveness of carvedilol for heart failure Delea T E, Vera-Llonch M, Richner R E, Fowler M B, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Use of carvedilol plus conventional therapy (digoxin, diuretics, and angiotensin-converting enzyme inhibitors) in the treatment of chronic heart failure (CHF). Type of intervention Secondary prevention and treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical patients with CHF. Setting Hospital. The economic study was carried out in the USA. Dates to which data relate Effectiveness data were obtained from studies published in 1991

NHS Economic Evaluation Database.1999

27. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.

Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. 9033462 1997 03 10 1997 03 10 2015 06 16 0140-6736 349 9049 1997 Feb 08 Lancet (London, England) Lancet Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. 375-80 (...) In patients with heart failure, beta-blocker therapy improves left-ventricular function after 3-6 months of treatment, but effects of such treatment on symptoms and exercise performance are inconsistent, and the longer-term effects on death and other serious clinical events remain uncertain. We have investigated these issues in a double-blind, placebo-controlled, randomised trial of the beta-adrenergic blocker carvedilol (which also has alpha 1-blocking properties). 415 patients with chronic stable heart

Lancet1997

28. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. 8614419 1996 06 05 1996 06 05 2013 05 28 0028-4793 334 21 1996 May 23 The New England journal of medicine N. Engl. J. Med. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. 1349-55 Controlled clinical trials have shown that beta-blockers can produce hemodynamic and symptomatic (...) placebo (n = 398) or the beta-blocker carvedilol (n = 696); background therapy with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor remained constant. Patient were observed for the occurrence death or hospitalization for cardiovascular reasons during the following 6 months, after the beginning (12 months for the group with mild heart failure). The overall mortality rate was 7.8 percent in the placebo group and 3.2 percent in the carvedilol group; the reduction in risk attributable

NEJM1996